Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AYESHA S LALL

Allopathic & Osteopathic Physicians Psychiatry & Neurology Child & Adolescent Psychiatry

NPI
1942221031
CMS profile
389680
Location
GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,751.71

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $2,289.37 2
Food and Beverage $462.34 4

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Boehringer Ingelheim Pharmaceuticals, Inc. $2,751.71 6

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AYESHA S LALL

NPI 1942221031 · CMS profile ID 389680

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Child & Adolescent Psychiatry

GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1942221031?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AYESHA S LALL, NPI 1942221031, CMS profile ID 389680. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942221031?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). AYESHA S LALL, NPI 1942221031, CMS profile ID 389680. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942221031?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
AYESHA S LALL, NPI 1942221031, CMS profile ID 389680, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1942221031?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $2,751.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $1,100.3302/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996928889 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $153.4102/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996928893 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $144.9302/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996928897 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,189.0402/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996928901 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $82.0002/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996928905 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $82.0002/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997137755 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $197.36 9
PY2020 $21.52 1
PY2021 $95.95 6
PY2022 $791.33 15
PY2023 $2,751.71 6
PY2024 $125.00 1
PY2025 $121.85 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $59,940.10 16
PY2024 Recipient $4,018.01 1
PY2024 Principal investigator $1,034,923.37 95
PY2023 Recipient $433.35 1
PY2023 Principal investigator $392,083.87 69
PY2022 Recipient $300.00 1
PY2022 Principal investigator $934,493.97 37
PY2021 Recipient $50.00 1
PY2021 Principal investigator $735,009.90 45
PY2020 Recipient $1,527.20 10
PY2020 Principal investigator $316,155.93 41
PY2019 Recipient $5,932.16 1
PY2019 Principal investigator $70,452.96 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

96 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $927.00 12/31/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
M23-515 Ph2 AD Global Study No dispute reported 06/30/2026 1100764793
Principal investigator 1 Janssen Research & Development, LLC $5,132.00 12/18/2024 Non-covered Recipient Entity
Vertex Rsrch Group
67953964MDD3003 No dispute reported 06/30/2026 1078954199
Principal investigator 1 Janssen Research & Development, LLC $181.00 12/04/2024 Non-covered Recipient Entity
Vertex Rsrch Group
67953964MDD3003 No dispute reported 06/30/2026 1078954141
Principal investigator 1 Janssen Research & Development, LLC $182.00 11/22/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954153
Principal investigator 1 Janssen Research & Development, LLC $5,988.00 11/15/2024 Non-covered Recipient Entity
Vertex Rsrch Group
67953964MDD3003 No dispute reported 06/30/2026 1078954197
Principal investigator 1 Janssen Research & Development, LLC $2,113.00 11/13/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954171
Principal investigator 1 Janssen Research & Development, LLC $3,855.00 11/11/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954163
Principal investigator 1 Janssen Research & Development, LLC $550.00 11/08/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954137
Principal investigator 1 Corium, LLC $2,500.00 11/07/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) No dispute reported 06/30/2026 1118400142
Principal investigator 1 Eli Lilly and Company $45,850.00 11/01/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137369960
Principal investigator 1 Janssen Research & Development, LLC $88.00 10/25/2024 Non-covered Recipient Entity
Vertex Rsrch Group
67953964MDD3003 No dispute reported 06/30/2026 1078954145
Principal investigator 1 Janssen Research & Development, LLC $1,030.00 10/25/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954167
Principal investigator 1 Janssen Research & Development, LLC $2,236.00 10/23/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954185
Principal investigator 1 Janssen Research & Development, LLC $264.00 10/23/2024 Non-covered Recipient Entity
Vertex Rsrch Group
67953964MDD3003 No dispute reported 06/30/2026 1078954191
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,500.00 10/18/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
ITI-007-505 No dispute reported 06/30/2026 1143139143
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $553.00 10/18/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
ITI-007-505 No dispute reported 06/30/2026 1143139147
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,250.00 10/18/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
ITI-007-505 No dispute reported 06/30/2026 1143139150
Principal investigator 1 Janssen Research & Development, LLC $10,559.00 10/16/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954129
Principal investigator 1 Janssen Research & Development, LLC $4,628.00 10/16/2024 Non-covered Recipient Entity
Vertex Rsrch Group
67953964MDD3003 No dispute reported 06/30/2026 1078954143
Principal investigator 1 Janssen Research & Development, LLC $77.00 10/14/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954131
Principal investigator 1 ABBVIE INC. $34,165.50 10/03/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100746834
Principal investigator 1 ABBVIE INC. $25,922.00 10/02/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100745098
Principal investigator 1 ABBVIE INC. $48,298.00 10/02/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100745100
Principal investigator 1 Janssen Research & Development, LLC $5,427.00 09/20/2024 Non-covered Recipient Entity
Vertex Rsrch Group
67953964MDD3003 No dispute reported 06/30/2026 1078954179
Principal investigator 1 ABBVIE INC. $125.00 09/18/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100743018
Principal investigator 1 ABBVIE INC. $22.93 09/18/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100743020
Principal investigator 1 ABBVIE INC. $565.65 09/18/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100743022
Principal investigator 1 ABBVIE INC. $439.80 09/18/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100743024
Principal investigator 1 ABBVIE INC. $159.30 09/18/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100743026
Principal investigator 1 ABBVIE INC. $58.39 09/18/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100743040
Principal investigator 1 ABBVIE INC. $196.47 09/18/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100743042
Principal investigator 1 ABBVIE INC. $4,500.00 09/18/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100743044
Principal investigator 1 ABBVIE INC. $502.20 09/18/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100743046
Principal investigator 1 Janssen Research & Development, LLC $362.00 09/18/2024 Non-covered Recipient Entity
Vertex Rsrch Group
67953964MDD3003 No dispute reported 06/30/2026 1078954169
Principal investigator 1 ABBVIE INC. $129.60 09/17/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100742520
Principal investigator 1 Janssen Research & Development, LLC $5,031.00 09/16/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954187
Principal investigator 1 Janssen Research & Development, LLC $13,976.00 08/27/2024 Non-covered Recipient Entity
Vertex Rsrch Group
67953964MDD3003 No dispute reported 06/30/2026 1078954161
Principal investigator 1 Janssen Research & Development, LLC $23,254.00 08/21/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954133
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $450.00 08/16/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
ITI-007-505 No dispute reported 06/30/2026 1143129065
Principal investigator 1 Janssen Research & Development, LLC $506.00 08/14/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954149
Principal investigator 1 Corium, LLC $2,000.00 08/08/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
An Efficacy and Safety Study w/ Azstarys in Children With ADHD No dispute reported 06/30/2026 1118399990
Principal investigator 1 Janssen Research & Development, LLC $362.00 08/07/2024 Non-covered Recipient Entity
Vertex Rsrch Group
67953964MDD3003 No dispute reported 06/30/2026 1078954159
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $16,000.00 08/02/2024 Non-covered Recipient Entity
Vertex Research Group
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1123481284
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 08/02/2024 Non-covered Recipient Entity
Vertex Rsrch Group
67953964MDD3003 No dispute reported 06/30/2026 1078954183
Principal investigator 1 Janssen Research & Development, LLC $947.00 07/17/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954195
Recipient Eli Lilly and Company $4,018.01 07/15/2024 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137346168
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $33,520.00 07/05/2024 Non-covered Recipient Entity
Vertex Research Group
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1123481282
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $54.00 07/05/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
ITI-007-505 No dispute reported 06/30/2026 1143127292
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $450.00 07/05/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
ITI-007-505 No dispute reported 06/30/2026 1143127295
Principal investigator 1 Janssen Research & Development, LLC $367.00 07/03/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954147
Principal investigator 1 ABBVIE INC. $113.71 07/02/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100725114
Principal investigator 1 ABBVIE INC. $85.84 07/02/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer s Disease No dispute reported 06/30/2026 1100725116
Principal investigator 1 Janssen Research & Development, LLC $1,621.00 06/24/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954173
Principal investigator 1 Janssen Research & Development, LLC $6,610.00 06/21/2024 Non-covered Recipient Entity
Vertex Rsrch Group
67953964MDD3003 No dispute reported 06/30/2026 1078954177
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,023.64 06/17/2024 Non-covered Recipient Entity
Vertex Clinical Research
A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of SPN-812 in Preschool-Age Children (4 to 5 years old) with Attention-Deficit/Hyperactivity Disorder (ADHD) No dispute reported 06/30/2026 1147771228
Principal investigator 1 Supernus Pharmaceuticals, Inc. $93.17 06/17/2024 Non-covered Recipient Entity
Vertex Clinical Research
A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of SPN-812 in Preschool-Age Children (4 to 5 years old) with Attention-Deficit/Hyperactivity Disorder (ADHD) No dispute reported 06/30/2026 1147771230
Principal investigator 1 Janssen Research & Development, LLC $12,834.00 06/12/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954165
Principal investigator 1 Supernus Pharmaceuticals, Inc. $683.75 06/06/2024 Non-covered Recipient Entity
Vertex Clinical Research
A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of SPN-812 in Preschool-Age Children (4 to 5 years old) with Attention-Deficit/Hyperactivity Disorder (ADHD) No dispute reported 06/30/2026 1147771226
Principal investigator 1 ABBVIE INC. $44,393.50 06/05/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100721174
Principal investigator 1 Janssen Research & Development, LLC $6,432.00 05/17/2024 Non-covered Recipient Entity
Vertex Rsrch Group
67953964MDD3003 No dispute reported 06/30/2026 1078954157
Principal investigator 1 Janssen Research & Development, LLC $7,989.00 05/13/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954181
Principal investigator 1 ABBVIE INC. $70,385.75 05/08/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100716274
Principal investigator 1 Janssen Research & Development, LLC $2,096.00 04/22/2024 Non-covered Recipient Entity
Vertex Rsrch Group
67953964MDD3003 No dispute reported 06/30/2026 1078954189
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,687.00 04/17/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
ITI-007-505 No dispute reported 06/30/2026 1143125505
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,450.00 04/17/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
ITI-007-505 No dispute reported 06/30/2026 1143125509
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,408.00 04/17/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
ITI-007-505 No dispute reported 06/30/2026 1143125513
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,810.00 04/17/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
ITI-007-505 No dispute reported 06/30/2026 1143125517
Principal investigator 1 Janssen Research & Development, LLC $28,500.00 04/17/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954155
Principal investigator 1 Eli Lilly and Company $400.00 04/10/2024 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137354632
Principal investigator 1 ABBVIE INC. $133,329.00 04/04/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100711604
Principal investigator 1 PFIZER INC. $1,500.00 04/04/2024 Non-covered Recipient Entity
VERTEX RESEARCH GROUP INC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1131060825
Principal investigator 1 Sumitomo Pharma America, Inc. $6,675.00 04/02/2024 Non-covered Recipient Entity
VERTEX RESEARCH GROUP
A Multi-region, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression) No dispute reported 06/30/2026 1148422602
Principal investigator 1 ABBVIE INC. $875.00 03/26/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100709824
Principal investigator 1 ABBVIE INC. $700.00 03/25/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100709678
Principal investigator 1 ABBVIE INC. $453.60 03/25/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100709680
Principal investigator 1 Janssen Research & Development, LLC $13,346.00 03/22/2024 Non-covered Recipient Entity
Vertex Rsrch Group
67953964MDD3003 No dispute reported 06/30/2026 1078954175
Principal investigator 1 ABBVIE INC. $159.30 03/21/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100709115
Principal investigator 1 ABBVIE INC. $139.35 03/21/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100709117
Principal investigator 1 ABBVIE INC. $4,120.20 03/21/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100709161
Principal investigator 1 Janssen Research & Development, LLC $42,389.00 03/20/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954193
Principal investigator 1 ABBVIE INC. $89,340.25 03/07/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100705978
Principal investigator 1 ABBVIE INC. $83.49 03/07/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100706042
Principal investigator 1 ABBVIE INC. $159.30 03/07/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100707040
Principal investigator 1 Janssen Research & Development, LLC $336.00 03/06/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954151
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $52,350.90 03/01/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUDEXTROMETHORPHAN HYDROBROMIDE [D6 DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 1118845488
Principal investigator 1 ABBVIE INC. $239.74 02/22/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100704670
Principal investigator 1 ABBVIE INC. $1,046.25 02/22/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100704672
Principal investigator 1 ABBVIE INC. $324.00 02/22/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100704674
Principal investigator 1 Janssen Research & Development, LLC $5,868.00 02/12/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954135
Principal investigator 1 ABBVIE INC. $39,978.00 02/01/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100701560
Principal investigator 1 Eisai Inc. $20,926.20 01/26/2024 Non-covered Recipient Entity
Compass Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529569
Principal investigator 1 Janssen Research & Development, LLC $7,040.00 01/17/2024 Non-covered Recipient Entity
Vertex Rsrch Group
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1078954139
Principal investigator 1 ABBVIE INC. $351.00 01/10/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100699637
Principal investigator 1 ABBVIE INC. $103,520.25 01/04/2024 Non-covered Recipient Entity
VERTEX CLINICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 1100698603
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $2,206.80 01/04/2024 Non-covered Recipient Entity
COMPASS RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN THE TREATMENT OF ADULTS WITH POST?TRAUMATIC STRESS DISORDER No dispute reported 06/30/2026 1118844840
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $96.54 01/01/2024 Non-covered Recipient Entity
Vertex Research Group
Connex 1 No dispute reported 06/30/2026 1101074635